The preclinical performance of the reported tracers was highly promising, both in absolute tumor uptake and ability to achieve high-contrast images rapidly, as highlighted by a CD38-targeting tracer that produced a ~ 96-fold tumor-to-muscle ratio within hours of injection. Here, CD38 is linked to neoplasm.